

Pio Conti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6929341/pio-conti-publications-by-year.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104 papers	4,452 citations	35 h-index	64 g-index
107 ext. papers	5,052 ext. citations	4.8 avg, IF	5.4 L-index

#	Paper	IF	Citations
104	Powerful anti-inflammatory action of luteolin: Potential increase with IL-38. <i>BioFactors</i> , 2021 , 47, 165-169.	10.1	5
103	Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
102	Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19. <i>Medical Hypotheses</i> , 2020 , 143, 109856	3.8	18
101	Advances in Mast Cell Activation by IL-1 and IL-33 in Sjögren's Syndrome: Promising Inhibitory Effect of IL-37. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
100	IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 16475-16480	11.5	13
99	Microglia and mast cells generate proinflammatory cytokines in the brain and worsen inflammatory state: Suppressor effect of IL-37. <i>European Journal of Pharmacology</i> , 2020 , 875, 173035	5.3	25
98	New aspect of allergic contact dermatitis, an inflammatory skin disorder mediated by mast cells: Can IL-38 help?. <i>Medical Hypotheses</i> , 2020 , 139, 109687	3.8	9
97	Impact of mast cells in fibromyalgia and low-grade chronic inflammation: Can IL-37 play a role?. <i>Dermatologic Therapy</i> , 2020 , 33, e13191	2.2	9
96	The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 607483	5.7	22
95	IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 21659-21665	11.5	22
94	New insight into systemic mastocytosis mediated by cytokines IL-1 and IL-33: Potential inhibitory effect of IL-37. <i>European Journal of Pharmacology</i> , 2019 , 858, 172473	5.3	1
93	Activation of mast cells mediates inflammatory response in psoriasis: Potential new therapeutic approach with IL-37. <i>Dermatologic Therapy</i> , 2019 , 32, e12943	2.2	7
92	IgE and macrophages for cancer rescue?. <i>EBioMedicine</i> , 2019 , 43, 7-8	8.8	
91	Human gingival mesenchymal stem cells pretreated with vesicular moringin nanostructures as a new therapeutic approach in a mouse model of spinal cord injury. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2019 , 13, 1109-1121	4.4	42
90	Mast Cells May Regulate The Anti-Inflammatory Activity of IL-37. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
89	Mast Cells Mediate Rheumatoid Arthritis-Inhibitory Role of IL-37. <i>Critical Reviews in Immunology</i> , 2019 , 39, 267-274	1.8	1
88	Recent progress on pathophysiology, inflammation and defense mechanism of mast cells against invading microbes: inhibitory effect of IL-37. <i>Central-European Journal of Immunology</i> , 2019 , 44, 447-454	1.6	0

87	Progression in migraine: Role of mast cells and pro-inflammatory and anti-inflammatory cytokines. <i>European Journal of Pharmacology</i> , 2019 , 844, 87-94	5.3	57
86	Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial. <i>Canadian Journal of Diabetes</i> , 2018 , 42, 568-573	2.1	14
85	Differential TBXA2 receptor transcript stability is dependent on the C924T polymorphism. <i>Prostaglandins and Other Lipid Mediators</i> , 2018 , 134, 141-147	3.7	2
84	Impact of mast cells in mucosal immunity of intestinal inflammation: Inhibitory effect of IL-37. <i>European Journal of Pharmacology</i> , 2018 , 818, 294-299	5.3	20
83	Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37. <i>Cell Proliferation</i> , 2018 , 51, e12475	7.9	22
82	Impact of Fungi on Immune Responses. <i>Clinical Therapeutics</i> , 2018 , 40, 885-888	3.5	7
81	Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers). <i>Immunologic Research</i> , 2018 , 66, 323-331	4.3	9
80	Autophagy processes are dependent on EGF receptor signaling. <i>Oncotarget</i> , 2018 , 9, 30289-30303	3.3	4
79	Impact of polyphenols on mast cells with special emphasis on the effect of quercetin and luteolin. <i>Central-European Journal of Immunology</i> , 2018 , 43, 476-481	1.6	16
78	Substance P and IL-33 administered together stimulate a marked secretion of IL-1 β from human mast cells, inhibited by methoxyluteolin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E9381-E9390	11.5	46
77	Mast cells participate in allograft rejection: can IL-37 play an inhibitory role?. <i>Inflammation Research</i> , 2018 , 67, 747-755	7.2	6
76	Immune Modulation by Vitamin D: Special Emphasis on Its Role in Prevention and Treatment of Cancer. <i>Clinical Therapeutics</i> , 2017 , 39, 884-893	3.5	28
75	Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. <i>Tissue and Cell</i> , 2017 , 49, 393-400	2.7	18
74	SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E4002-E4009	11.5	81
73	Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study. <i>Cardiology and Therapy</i> , 2017 , 6, 261-271	2.8	
72	Anti-inflammatory effects of hypoxia-preconditioned human periodontal ligament cell secretome in an experimental model of multiple sclerosis: a key role of IL-37. <i>FASEB Journal</i> , 2017 , 31, 5592-5608	0.9	52
71	Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. <i>Immunologic Research</i> , 2017 , 65, 982-986	4.3	9
70	Reply to Fattori et al.: Action of SP and IL-33 on mast cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E10036	11.5	

69	Link between mast cells and bacteria: Antimicrobial defense, function and regulation by cytokines. <i>Medical Hypotheses</i> , 2017 , 106, 10-14	3.8	13
68	Neuroendocrinology of the skin. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016 , 17, 287-294	10.5	27
67	Comparison of Serum Total Valproic Acid Levels and %CDT Values in Chronic Alcohol Addictive Patients in an Italian Clinic: A Retrospective Study. <i>Drugs - Real World Outcomes</i> , 2016 , 3, 7-12	2.2	4
66	Important role of mast cells in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 5, 77-80	4	34
65	The Role of Mast Cells in Alzheimer's Disease. <i>Advances in Clinical and Experimental Medicine</i> , 2016 , 25, 781-7	1.8	30
64	Are mast cells important in diabetes?. <i>Polish Journal of Pathology</i> , 2016 , 67, 199-206	0.9	9
63	Key Role of DAMP in Inflammation, Cancer, and Tissue Repair. <i>Clinical Therapeutics</i> , 2016 , 38, 1017-28	3.5	109
62	Targeting IL-33 in autoimmunity and inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 354, 24-31	4.7	65
61	Atherosclerosis: a chronic inflammatory disease mediated by mast cells. <i>Central-European Journal of Immunology</i> , 2015 , 40, 380-6	1.6	85
60	Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. <i>Clinical Therapeutics</i> , 2015 , 37, 984-95	3.5	325
59	Spectrum of mast cell activation disorders. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 729-39	5.1	43
58	Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. <i>Journal of Clinical Psychopharmacology</i> , 2014 , 34, 187-9	1.7	21
57	The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011 , 10, 119-32	2.6	45
56	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 54-68	7	70
55	IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 4448-53	11.5	225
54	IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. <i>European Journal of Dermatology</i> , 2010 , 20, 865-7	0.8	31
53	Recent insights in primary immunodeficiency diseases: the role of T-lymphocytes and innate immunity. <i>Annals of Clinical and Laboratory Science</i> , 2010 , 40, 3-9	0.9	3
52	Evidence of hepatitis C virus-specific interferon gamma-positive T cells in health care workers in an infectious disease department. <i>American Journal of Infection Control</i> , 2009 , 37, 426-429	3.8	6

51	Environmental and occupational stress and autoimmunity. <i>Autoimmunity Reviews</i> , 2008 , 7, 340-3	13.6	44
50	Impact of stress and mast cells on brain metastases. <i>Journal of Neuroimmunology</i> , 2008 , 205, 1-7	3.5	46
49	Novel therapeutic targets for autism. <i>Trends in Pharmacological Sciences</i> , 2008 , 29, 375-82	13.2	48
48	Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. <i>Journal of Medical Virology</i> , 2008 , 80, 1900-6	19.7	31
47	Differential release of mast cell mediators and the pathogenesis of inflammation. <i>Immunological Reviews</i> , 2007 , 217, 65-78	11.3	314
46	The relationship between Bcl-gene expression and learning and memory impairment in chronic aluminum-exposed rats. <i>Neurotoxicity Research</i> , 2007 , 12, 163-9	4.3	30
45	Expression and secretion of CXCL8 (IL-8), release of tryptase and transcription of histidine decarboxylase mRNA by anti-IgE-activated human umbilical cord blood-derived cultured mast cells. <i>NeuroImmunoModulation</i> , 2007 , 14, 97-104	2.5	2
44	Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 58-61	1.7	41
43	Role of mast cells in tumor growth. <i>Annals of Clinical and Laboratory Science</i> , 2007 , 37, 315-22	0.9	48
42	Inhibitory effect of quercetin on tryptase and MCP-1 chemokine release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. <i>NeuroImmunoModulation</i> , 2006 , 13, 179-86	2.5	7
41	Modulation of MCP-1 and iNOS by 50-Hz sinusoidal electromagnetic field. <i>Nitric Oxide - Biology and Chemistry</i> , 2006 , 15, 50-7	5	48
40	Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. <i>Clinical and Experimental Medicine</i> , 2006 , 6, 150-6	4.9	40
39	Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. <i>Journal of Neuroimmunology</i> , 2004 , 148, 162-71	3.5	101
38	Mast cells as targets of corticotropin-releasing factor and related peptides. <i>Trends in Pharmacological Sciences</i> , 2004 , 25, 563-8	13.2	246
37	Mast cells: the Jekyll and Hyde of tumor growth. <i>Trends in Immunology</i> , 2004 , 25, 235-41	14.4	262
36	Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 314-21	1.7	39
35	IL-10, an inflammatory/inhibitory cytokine, but not always. <i>Immunology Letters</i> , 2003 , 86, 123-9	4.1	176
34	Transcription and translation of the chemokines RANTES and MCP-1 in nasal polyps and mucosa in allergic and non-allergic rhinopathies. <i>Immunology Letters</i> , 2003 , 90, 71-5	4.1	11

33	IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. <i>Immunology Letters</i> , 2003 , 88, 171-4	4.1	71
32	Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. <i>Allergy and Asthma Proceedings</i> , 2003 , 24, 285-90	2.6	55
31	Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002 , 123, 170-9	3.5	23
30	Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2002 , 51, 91-8	7.4	25
29	MCP-1 and MIP-2 response in <i>Trichinella spiralis</i> infected mice treated with 4-deoxypyridoxine (4-DPD). <i>Immunology Letters</i> , 2002 , 83, 31-7	4.1	5
28	Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee. <i>Immunology Letters</i> , 2002 , 80, 105-11	4.1	28
27	Inhibition of MCP-1 and MIP-2 transcription and translation by mimosine in muscle tissue infected with the parasite <i>Trichinella spiralis</i> . <i>Molecular and Cellular Biochemistry</i> , 2002 , 229, 129-37	4.2	13
26	Interleukin-16 network in inflammation and allergy. <i>Allergy and Asthma Proceedings</i> , 2002 , 23, 103-8	2.6	23
25	Differential expression and secretion of RANTES and MCP-1 in activated peripheral blood mononuclear cell cultures of atopic subjects. <i>Immunology Letters</i> , 2001 , 76, 7-14	4.1	8
24	Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001 , 21, 327-34	9.4	189
23	MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia. <i>Atherosclerosis</i> , 2001 , 155, 53-9	3.1	19
22	Effects of low frequency electromagnetic fields on expression of lymphocyte subsets and production of cytokines of men and women employed in a museum. <i>Science of the Total Environment</i> , 2001 , 270, 13-20	10.2	23
21	Lymphocyte subset changes in blood and gastrointestinal mucosa after oral nickel challenge in nickel-sensitized women. <i>Contact Dermatitis</i> , 2000 , 43, 206-11	2.7	36
20	RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. <i>Journal of Neuroimmunology</i> , 2000 , 107, 100-7	3.5	54
19	Increase in CD45RO+ cells and activated eosinophils in chronic allergic conjunctivitis. <i>Immunobiology</i> , 2000 , 201, 541-51	3.4	5
18	Localization of the e-NOS enzyme in endothelial cells and odontoblasts of healthy human dental pulp. <i>Life Sciences</i> , 2000 , 68, 297-306	6.8	32
17	Impact of extremely low frequency electromagnetic fields on CD4 expression in peripheral blood mononuclear cells. <i>Molecular and Cellular Biochemistry</i> , 1999 , 201, 49-55	4.2	12
16	Effect of electromagnetic fields on several CD markers and transcription and expression of CD4. <i>Immunobiology</i> , 1999 , 201, 36-48	3.4	5

15	Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw. <i>British Journal of Haematology</i> , 1998 , 103, 798-803	4.5	24
14	Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/WV mice. <i>FASEB Journal</i> , 1998 , 12, 1693-700	0.9	68
13	Monocyte chemotactic protein 1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells. <i>Journal of Vascular Research</i> , 1997 , 34, 58-65	1.9	58
12	Impact of Rantes and MCP-1 Chemokines on In Vivo Basophilic Cell Recruitment in Rat Skin Injection Model and Their Role in Modifying the Protein and mRNA Levels for Histidine Decarboxylase. <i>Blood</i> , 1997 , 89, 4120-4127	2.2	116
11	Infra-red laser irradiation enhances interleukin-1 receptor antagonist, increases 3H-thymidine incorporation and the release of [3H]arachidonic acid in human monocytes. <i>Molecular and Cellular Biochemistry</i> , 1997 , 169, 51-9	4.2	1
10	RANTES is a pro-inflammatory chemokine and chemoattracts basophil cells to extravascular sites. <i>Journal of Pathology</i> , 1997 , 183, 352-8	9.4	22
9	Generation of TNF alpha, IFN gamma, IL-6, IL-4 and IL-10 in mouse serum from trichinellosis: effect of the anti-inflammatory compound 4-deoxypyridoxine (4-DPD). <i>Immunology Letters</i> , 1996 , 49, 179-84	4.1	32
8	Effect of interleukin-1 receptor antagonist (IL-1RA) on histamine and serotonin release by rat basophilic leukemia cells (RBL-2H3) and peritoneal mast cells. <i>Molecular and Cellular Biochemistry</i> , 1996 , 155, 61-8	4.2	7
7	Synergistic activation of serum amyloid A (SAA) by IL-6 and IL-1 in combination on human Hep 3B hepatoma cell line. Role of PGE2 and IL-1 receptor antagonist. <i>Immunological Investigations</i> , 1995 , 24, 523-35	2.9	24
6	Inhibition of leukotriene B4(LTB4) by recombinant interleukin-1 receptor antagonist (IL-1RA) on human monocytes. <i>Agents and Actions</i> , 1992 , 36, C93-C95		1
5	Inhibition of leukotriene B4(LTB4) by recombinant interleukin-1 receptor antagonist (IL-1RA) on human monocytes. <i>Agents and Actions</i> , 1992 , 36, C93-C95		
4	Human recombinant interleukin-1 receptor antagonist inhibits lymphocyte blastogenesis induced by concanavalin A. Restorative effect of hrIL-1. <i>FEBS Letters</i> , 1991 , 286, 137-41	3.8	14
3	Effect of Electromagnetic Fields on Two Calcium Dependent Biological Systems. <i>Journal of Bioelectricity</i> , 1985 , 4, 227-236		27
2	Reduced mitogenic stimulation of human lymphocytes by extremely low frequency electromagnetic fields. <i>FEBS Letters</i> , 1983 , 162, 156-60	3.8	90
1	Mast Cells Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-inflammatory Cytokines IL-37, IL-38 and IL-1Ra		4